- Home
- FLYE vs IMRN Comparison
FLYE vs IMRN Comparison
Compare FLYE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- IMRN
- Stock Information
- Founded
- FLYE 2018
- IMRN 1994
- Country
- FLYE United States
- IMRN Australia
- Employees
- FLYE N/A
- IMRN N/A
- Industry
- FLYE Aerospace
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- IMRN Health Care
- Exchange
- FLYE Nasdaq
- IMRN Nasdaq
- Market Cap
- FLYE 10.7M
- IMRN 15.0M
- IPO Year
- FLYE 2024
- IMRN N/A
- Fundamental
- Price
- FLYE $0.41
- IMRN $1.96
- Analyst Decision
- FLYE
- IMRN Strong Buy
- Analyst Count
- FLYE 0
- IMRN 1
- Target Price
- FLYE N/A
- IMRN $5.00
- AVG Volume (30 Days)
- FLYE 181.1K
- IMRN 6.0K
- Earning Date
- FLYE 02-10-2025
- IMRN 12-31-2024
- Dividend Yield
- FLYE N/A
- IMRN N/A
- EPS Growth
- FLYE N/A
- IMRN N/A
- EPS
- FLYE N/A
- IMRN N/A
- Revenue
- FLYE $30,297,313.00
- IMRN $3,271,194.00
- Revenue This Year
- FLYE N/A
- IMRN N/A
- Revenue Next Year
- FLYE N/A
- IMRN N/A
- P/E Ratio
- FLYE N/A
- IMRN N/A
- Revenue Growth
- FLYE 14.77
- IMRN 171.67
- 52 Week Low
- FLYE $0.38
- IMRN $1.59
- 52 Week High
- FLYE $7.62
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- IMRN 45.89
- Support Level
- FLYE N/A
- IMRN $2.05
- Resistance Level
- FLYE N/A
- IMRN $2.23
- Average True Range (ATR)
- FLYE 0.00
- IMRN 0.17
- MACD
- FLYE 0.00
- IMRN -0.00
- Stochastic Oscillator
- FLYE 0.00
- IMRN 29.69
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.